PRODUCT LITERATURE

Benefit-Risk Assessment of Rosuvastatin 10 to 40 Milligrams

---

The aim of this article is to examine the benefit-risk profile of rosuvastatin at doses of 10 to 40 mg. In dyslipidemic patients, rosuvastatin produced markedly greater reductions in low-density lipoprotein (LDL) cholesterol and equivalent or greater improvements in various lipid measures, including high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, and triglycerides when compared with atorvastatin, simvastatin, and pravastatin

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Rosufer

Specific Detail Info

Am J Cardiol 2003;92(suppl):23K–29K

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment